AlphaVax Inc., of Research Triangle Park, N.C., promoted Jonathan Smith to chief scientific officer.

Cambrex Corp., of East Rutherford, N.J., appointed Edward Robinson executive vice president, Europe, of the pharma and biopharmaceutical division.

Celltech Group plc, of London, appointed Grahaem Brown as director of development.

Curis Inc., of Cambridge, Mass., named Michael Gray vice president of finance and chief financial officer, and appointed Christopher Missling senior vice president, strategic analysis and planning.

Cytomedix Inc., of Little Rock, Ark., added Mark Cline as president and William Allender as chief financial officer.

Elixir Pharmaceuticals Inc., of Cambridge, Mass., established a clinical advisory board, consisting of Andrew Bodner, George Daley, Edward Scolnick and Bennett Shapiro.

Emisphere Technologies Inc., of Tarrytown, N.Y., appointed Elliot Maza chief financial officer.

GPC Biotech AG, of Martinsried, Germany, named Michael Lytton to replace Helmut Schühsler as vice chairman of its supervisory board.

Graffinity Pharmaceuticals AG, of Heidelberg, Germany, appointed Paul Edwards associate director of medicinal chemistry.

Guilford Pharmaceuticals Inc., of Baltimore, appointed David U'Prichard to its board and to the board's science committee.

Hydra Biosciences Inc., of Cambridge, Mass., named Glenn Larsen chief scientific officer; executive vice president, research and development; and a board member.

Intercell AG, of Vienna, Austria, added David Ebsworth to its supervisory board.

Kaye Scholer LLP, of New York, added Leora Ben-Ami, Thomas Fleming and Patricia Carson as partners.

Myriad Genetics Inc., of Salt Lake City, elected Robert Attiyeh to its board.

NitroMed Inc., of Bedford, Mass., appointed Davey Scoon to its board, which he will serve as chairman of the audit committee.

Pennsylvania Biotechnology Association added Boyd Clarke, Ronald Herberman and Les Hudson to its board.

Prestwick Pharmaceuticals Inc., of Washington, appointed Christopher O'Brien chief medical officer.

Transkaryotic Therapies Inc., of Cambridge, Mass., added Lydia Villa-Komaroff and Dennis Langer to its board.

VaxGen Inc., of Brisbane, Calif., named Franklin Berger to its board.

Viragen Inc., of Plantation, Fla., elected Randolph Pohlman as a director.

Vivus Inc., of Mountain View, Calif., appointed James Nickel as vice president of clinical medicine.

Xechem International Inc., of New Brunswick, N.J., named William Pursley president and chief operating officer.